MaxCyte Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 revenue met expectations but declined year-over-year due to SPL program turnover and inventory management. Guidance for 2026 is reiterated, with revenue weighted to the second half and a $10 million share repurchase program authorized.
Fiscal Year 2025
-
2025 saw revenue decline 15% year-over-year amid SPL program exits and inventory headwinds, but new product launches, cost restructuring, and a strong balance sheet position the company for growth. 2026 guidance anticipates $30–32 million in revenue, with a back-half weighted recovery and material contributions from SeQure Dx and SPL milestones.
-
Recent restructuring and the SecureDx acquisition have sharpened focus on early-stage customer engagement and safety in cell and gene therapy. Despite industry headwinds, strong gross margins, cost reductions, and new product launches position the business for renewed growth and global expansion in 2026.
-
Q3 2025 revenue declined year-over-year but met expectations, with cost-saving restructuring underway and a strong SPL pipeline. SecureDX integration and new product launches are expected to drive growth in 2026, while the company maintains a robust cash position and disciplined M&A focus.
-
Q2 2025 revenue declined 18% year-over-year, prompting a reduction in 2025 core revenue guidance due to customer program rationalizations and capital equipment hesitancy. Despite headwinds, instrument sales grew 22% and new SPLs were signed, with growth expected to resume in 2026.
-
Q1 2025 revenue declined 8% year-over-year to $10.4M, but core revenue was stable and gross margins remained strong. SecureDX integration is progressing, and 2025 guidance for revenue growth and SPL program-related revenue was reaffirmed.
-
The ExPERT platform's high-efficiency, scalable electroporation is driving growth in cell and gene therapy, especially as the industry shifts toward allogeneic and autoimmune applications. Strategic acquisitions like SeQure Dx and robust SPL economics position the company for continued expansion and profitability.
Fiscal Year 2024
-
Core revenue grew 9% in 2024, driven by strong PA sales and strategic improvements, despite a 6% decline in total revenue due to prior year milestones. The SeQure Dx acquisition expands service offerings and market reach, with 2025 guidance projecting 8%-15% core revenue growth and continued SPL portfolio expansion.
-
Leadership emphasized renewed focus on cell and gene therapy, operational excellence, and expanding product offerings. The electroporation platform is validated by commercial approvals and strong SPL growth, with robust financials and a positive long-term outlook.
-
Cell and gene therapy markets are shifting toward non-viral, ex vivo approaches, with electroporation gaining traction for complex edits. Financial performance improved in 2024, driven by strong cell therapy activity and SPL growth. Regulatory support and new approvals in solid tumors signal broader market opportunities.
-
Q3 2024 revenue grew 2% year-over-year to $8.2M, with core revenue up 23% and strong cell therapy growth. Six new SPLs were signed, a record, and guidance for 2024 core revenue growth was raised to at least 5%. Gross margin was impacted by a one-time write-off, but cash remains strong.
-
Q2 2024 revenue rose 15% year-over-year to $10.4 million, driven by SPL program-related growth and stable core business, despite cautious customer spending. Five new SPLs were signed, and year-end cash guidance was raised to $180 million. Gross margin improved to 86%.
-
Cell and gene therapy is rapidly advancing, with non-viral ex vivo engineering enabling new curative treatments and expanding into diverse indications. The platform's robust technology and business model support a growing pipeline, high margins, and strong financials, as seen with recent product approvals and new licenses.